DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Bisphosphonate
Bisphosphonate
1.1. Bisphosphonates and Depressive Reactions
Association Between Oral Anticoagulants and Osteoporosis
Proton Pump Inhibitors and Fracture Risk: a Review of Current Evidence and Mechanisms Involved
Prevention of Glucocorticoid-Induced Osteoporosis
Bisphosphonates: Mechanisms of Action
Conjugated Bisphosphonate with High Affinity for Bone As a Bone
Legacy Drug-Prescribing Patterns in Primary Care
Denosumab: a New Therapy for Osteoporosis Editor by Candice Gehret, Pharm.D
Osteoporosis in Depression: Which Patients Are at Risk?
Dr Alex Comninos
Guidelines for Bisphosphonate-Associated Osteonecrosis of the Jaw
Risks of Bisphosphonate
(Alendronate) Initiation After Surgery for Fragility Fracture: a Population-Based Cohort Study
Bisphosphonates and Glucocorticoid-Induced
Synergistic Autophagy Effect of Mir-212-3P in Zoledronic Acid
Case Study of Hydrometra and Uterine Adenocarcinoma in a Pet Rabbit
Osteonecrosis of the Jaw Related to Everolimus and Bisphosphonate: a Unique Case Report?
Combined Therapy with a New Bisphosphonate, Minodronate
Top View
Update in Geriatrics
Summary of Product Characteristics
FOSAMAX PLUS D Safely and Effectively
PBC Primary Biliary Cholangitis Treatment and Management
Bisphosphonate Therapy
Primary Biliary Cirrhosis View Online At
The Change of Bone Mineral Density by Bisphosphonates Therapy with Calcium-Antagonists in Osteoporosis
Bisphosphonate Treatment: an Orthodontic Concern Calling for a Proactive Approach
1 American Association of Oral and Maxillofacial Surgeons Position
Use of Anti-Osteoporosis Medication Dispensing by Patients with Hip Fracture: Could We Do Better?
Zoledronic Acid Potentiates Mtor Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process
Adjuvant Bisphosphonate
Bisphosphonate Safety
Perio Reports Vol. 22 No. 9 Perio Reports Provides Easy-To-Read Research Summaries on Topics of Specific Interest to Clinicians
(70 Mg/70 Mcg Tablet) FOSAMAX PLUS™ 70/140
Primary Sjogren Syndrome Increases the Risk of Bisphosphonate-Related
BMD at Bisphosphonate's End Predicts Fractures
Bisphosphonate-Associated Osteonecrosis
Fractured Hip Discharge Prescription
Alendronate-Associated Rhabdomyolysis in a Patient with Other Risk Factors
Evaluation of Antidepressant Effects of Zoledronate in Rats
Diagnosis and Treatment of Osteoporosis
AAE Position Statement, Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of The
Bisphosphonate Treatment of Osteogenesis Imperfecta
NOGG 2017: Clinical Guideline for the Prevention and Treatment of Osteoporosis
Pharmacology of Bisphosphonates
Osteonecrosis of the Jaw Associated with the Use of Bisphosphonates
Association Between Concomitant Use Of
Bone Health and Osteoporosis Management of the Patient with Duchenne Muscular Dystrophy Leanne M
Rare Forms of Dementia
Bisphosphonate Treatment and Pregnancy
Bisphosphonate-Based Conjugates and Derivatives As Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer
Use of Platelet Rich Fibrin (PRF)-Based Autologous Membranes for Tooth Extraction in Patients Under Bisphosphonate Therapy: a Case Report
Zoledronic Acid-Induced Cytotoxicity Through Endoplasmic Reticulum Stress Triggered REDD1-Mtor Pathway in Breast Cancer Cells
Managing the Care of Patients Receiving Antiresorptive Therapy
Fosamax® (Alendronate Sodium) Tablets and Oral Solution
Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines
Deprescribing
Bisphosphonates: Mode of Action and Pharmacology
Osteoporosis Screening and Management
Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles Following Fluid-Phase Endocytosis
Osteonecrosis of the Jaw As an Adverse Bisphosphonate Event: Three Cases of Bone Metastatic Prostate Cancer Patients Treated with Zoledronic Acid
Medication-Related Osteonecrosis of the Jaw with the Mtor Inhibitor
Prevention and Management of Glucocorticoid-Induced Side Effects: a Comprehensive Review
Pharmacologic Prevention of Osteoporotic Fractures THOMAS M
Osteoporosis Screening, Diagnosis, and Treatment Guideline
Effectiveness of Statin and Bisphosphonate Treatment in a 3NP Model of Huntington’S Disease
PATIENT FACT SHEET Therapy
HT & Antidepressant Response
Bisphosphonate-Associated Osteonecrosis of the Jaw
Clinical Pearls: Geriatrics
Pharmacological Therapy of Osteoporosis Pediatric Endocrinology June 2018
Drug Induced Injury of GIT
Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate
Administration of Mtor Inhibitors
Opposing Effects of Bisphosphonates and Advanced Glycation End-Products on Osteoblastic Cells
Fosamax® (Alendronate Sodium) Tablets and Oral Solution
Bisphosphonates in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Highlights of Prescribing Information
Use of Antidepressants and Rates of Hip Bone Loss in Older Women the Study of Osteoporotic Fractures
Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Tricyclic Antidepressant Use and Risk of Fractures: a Meta-Analysis of Cohort Studies Through the Use of Both Frequentist and Bayesian Approaches
Rxfiles Osteoporosis, Vit D, SMBG & Anti-Infectives 2010
The Role of Dental Care Providers in the Management of Patients Prescribed Bisphosphonates: Brief Clinical Guidance
Bisphosphonates for Treating Osteoporosis
Proton Pump Inhibitor (PPI) Policy